Histolix has raised $1M in SAFE funding and has completed its initial equivalency validation trial which demonstrated an FDA level of performance (under 4% discordance) as a primary diagnostic tool.* With a blinded study of 100 tissues and 22 tissue types with four third party expert readers, Histolix demonstrated its under 5 minute direct to digital imaging equivalence to standardized H&E diagnosis which takes days to weeks to complete. Histolix is now raising up to $15M in its Series A round, the funds of which will be used to finalize FDA trials in preparation for commercial launch.
* Click here to see Med Archives Publication. FDA trials will commence 2023.